Cargando…

Diagnostic and treatment strategies in mucopolysaccharidosis VI

Mucopolysaccharidosis VI (MPS VI) is a very rare autosomal recessive disorder caused by mutations in the ARSB gene, which lead to deficient activity of the lysosomal enzyme ASB. This enzyme is important for the breakdown of the glycosaminoglycans (GAGs) dermatan sulfate and chondroitin sulfate, whic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vairo, Filippo, Federhen, Andressa, Baldo, Guilherme, Riegel, Mariluce, Burin, Maira, Leistner-Segal, Sandra, Giugliani, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634832/ https://www.ncbi.nlm.nih.gov/pubmed/26586959 http://dx.doi.org/10.2147/TACG.S68650

Ejemplares similares

Relative frequency and estimated minimal frequency of Lysosomal Storage Diseases in Brazil: Report from a Reference Laboratory
por: Giugliani, Roberto, et al.
Publicado: (2017)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
por: Giugliani, Roberto, et al.
Publicado: (2010)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Information and Diagnosis Networks – tools to improve diagnosis and treatment for patients with rare genetic diseases
por: Vieira, Taiane Alves, et al.
Publicado: (2019)

Lysosomal diseases: Overview on current diagnosis and treatment
por: Poswar, Fabiano de Oliveira, et al.
Publicado: (2019)

Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)
por: Poswar, Fabiano de Oliveira, et al.
Publicado: (2022)

Rare disease landscape in Brazil: report of a successful experience in inborn errors of metabolism
por: Giugliani, Roberto, et al.
Publicado: (2016)

Effects of Enzyme Replacement Therapy Started Late in a Murine Model of Mucopolysaccharidosis Type I
por: Pasqualim, Gabriela, et al.
Publicado: (2015)

Visual impairment in mucopolysaccharidosis VI
por: Magalhães, Augusto Monteiro, et al.
Publicado: (2023)

Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI
por: Tulebayeva, Assel, et al.
Publicado: (2020)

Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome): a case report
por: Andrade, Isadora, et al.
Publicado: (2022)

Diagnosing mucopolysaccharidosis IVA
por: Wood, Timothy C., et al.
Publicado: (2013)

Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI
por: Harmatz, Paul R., et al.
Publicado: (2013)

Vertebral Tongue-Like Deformity in Mucopolysaccharidosis VI
por: Landen, Michiel, et al.
Publicado: (2021)

Epidemiology and Genetics of Mucopolysaccharidosis Type VI in Russia
por: Voskoboeva, Elena, et al.
Publicado: (2022)

Mucopolysaccharidosis Type VI, an Updated Overview of the Disease
por: D’Avanzo, Francesca, et al.
Publicado: (2021)

Mucopolysaccharidosis Type VI with Recurrent Chest Infection
por: Numan, Ashraf, et al.
Publicado: (2023)

Cardiac disease as the presenting feature of mucopolysaccharidosis type IIIA: A case report
por: Ribeiro, Erlane Marques, et al.
Publicado: (2014)

Intellectual Disability in a Birth Cohort: Prevalence, Etiology, and Determinants at the Age of 4 Years
por: Karam, Simone M., et al.
Publicado: (2016)

Diagnosis of Mucopolysaccharidoses
por: Kubaski, Francyne, et al.
Publicado: (2020)

Visual Dysfunction of Type I and VI Mucopolysaccharidosis Patients Evaluated with Visual Evoked Cortical Potential
por: Gomes, Bruno Duarte, et al.
Publicado: (2012)

Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I
por: Giugliani, Roberto, et al.
Publicado: (2021)

Mucopolysaccharidosis VI in cats – clarification regarding genetic testing
por: Lyons, Leslie A., et al.
Publicado: (2016)

Clinical findings in Brazilian patients with adult GM1 gangliosidosis
por: Giugliani, Luciana, et al.
Publicado: (2019)

Genetic causes of intellectual disability in a birth cohort: A population‐based study
por: Karam, Simone M., et al.
Publicado: (2015)

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I
por: Giugliani, Roberto, et al.
Publicado: (2017)

Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012)

Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase
por: Brands, Marion M, et al.
Publicado: (2013)

Hemifacial Spasm in Mucopolysaccharidosis Type VI (Maroteaux–Lamy Syndrome)
por: Karir, Aneesh, et al.
Publicado: (2018)

Analysis of Mucopolysaccharidosis Type VI through Integrative Functional Metabolomics
por: Tebani, Abdellah, et al.
Publicado: (2019)

RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis
por: Wiesinger, Anna-Maria, et al.
Publicado: (2023)

Respiratory and sleep disorders in mucopolysaccharidosis
por: Berger, Kenneth I., et al.
Publicado: (2012)

Phenotype-oriented NGS panels for mucopolysaccharidoses: Validation and potential use in the diagnostic flowchart
por: Brusius-Facchin, Ana Carolina, et al.
Publicado: (2019)

Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene
por: Tomanin, Rosella, et al.
Publicado: (2018)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Haploidentical stem cell transplantation in two children with mucopolysaccharidosis VI: clinical and biochemical outcome
por: Jester, Sandra, et al.
Publicado: (2013)

Population medical genetics: translating science to the community
por: Giugliani, Roberto, et al.
Publicado: (2019)

A case of mucopolysaccharidosis type VI in a polish family. Importance of genetic testing and genotype-phenotype relationship in the diagnosis of mucopolysaccharidosis
por: Zapała, Barbara, et al.
Publicado: (2020)

Precision Medicine for Lysosomal Disorders
por: Pinto e Vairo, Filippo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dlkmn6s9manvc2vp97fc36l9c4